Vivoryon Therapeutics N.V. announced the appointment of Anne Doering as Chief Financial Officer (CFO), leveraging Ms. Doering?s deep capital markets experience and enabling a smooth management transition as she succeeds Florian Schmid on March 1, 2024.
Market Closed -
Other stock markets
|
After market 02:05:45 pm | |||
0.648 EUR | -13.94% | 0.663 | +2.31% |
Apr. 24 | Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024 | |
Mar. 15 | Vivoryon Therapeutics N.V Announces Resignation of Board of Directors | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-92.04% | 21.03M | |
+0.62% | 42.86B | |
+12.11% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.89% | 25.15B | |
-23.61% | 18.63B | |
+28.35% | 12.37B | |
-3.39% | 11.92B | |
+6.98% | 11.21B |
- Stock Market
- Equities
- VVY Stock
- News Vivoryon Therapeutics N.V.
- Vivoryon Therapeutics N.V. Announces Executive Changes